EX-4.4 5 v036643_ex4-4.htm
Exhibit 4.4






February 27, 2006

Smithfield Fiduciary LLC
c/o Highbridge Capital Management, LLC
9 West 57th Street
27th Floor
New York, New York
USA 10019
Attention:        Ari J. Storch / Adam J. Chill


Dear Sirs:

Re:
Generex Biotechnology Corporation
- Amendments to Warrants

We make reference to (a) the common stock purchase warrant issued by Generex Biotechnology Corporation (the “Company”) to Smithfield Fiduciary LLC (“Smithfield”) on October 27, 2005 pursuant to which the Company granted to Smithfield the entitlement to purchase up to 609,756 shares of the Company’s common stock at $1.25 per share, (b) the common stock purchase warrant issued by the Company to Smithfield on October 27, 2005 pursuant to which the Company granted to Smithfield the entitlement to purchase up to 304,878 shares of the Company’s common stock at $1.25 per share, and (c) the common stock purchase warrant issued by the Company to Smithfield on January 20, 2006 pursuant to which the Company granted to Smithfield the entitlement to purchase up to 952,381 shares of the Company’s common stock at $1.05 per share (collectively, the “Warrants”).

The Initial Exercise Date (as that term is defined in each of the Warrants) of each of the Warrants is expressed therein as the 181st day after the date thereof. The Company hereby confirms that, in consideration of the exercise by Smithfield of not less than 100% of the Warrants and the delivery to the Company of Notices of Exercise in respect thereof on or before the close of business on February 27, 2006, the Company has agreed to abridge the Initial Exercise Dates and to honor the aforementioned Notices of Exercise.

 
 
 


In addition, the Company will grant to Smithfield an additional common stock purchase warrant pursuant to which the Company will grant to Smithfield the entitlement to purchase up to 933,508 shares of the Company’s common stock at $3.00 per share exercisable for a period of five years from and after August 27, 2006.

Yours truly,

Generex Biotechnology Corporation


/s/ Mark A. Fletcher             
Mark A. Fletcher
Executive Vice-President, General Counsel
maf:hs